About Us

We address the underlying causes of ophthalmic diseases

Enhancing Lives & Better Vision

Okogen is an ophthalmic specialty pharmaceutical company focused on developing the leading treatment for both bacterial and viral conjunctivitis.

Our lead product candidate, OKG-0303, is being developed to treat infectious conjunctivitis. It is a fixed dose eyedrop consisting of a proprietary antiviral, an ocular decongestant and an antibacterial agent.

There are 6 million new cases of acute conjunctivitis per year in United States.

Meet the Team


Bradford A. Conlan

Read More

Joshua H. Moriarty

Read More

Board of Directors

Brian M Strem, PhD

Read More

Eric Daniels, MD, MBA

Read More

Quinton Oswald

Read More

Scientific & Medical Advisory Board

Francis Mah, MD

Jay Pepose, MD, PhD

John Sheppard, MD

Russel Van Gelder, MD, PhD

Stephanie Watson, MD